Trial Profile
A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 30 Sep 2011 Actual initiation date (September 2006) added as reported by ClinicalTrials.gov.
- 20 Jan 2011 Results published in Vaccine.
- 09 Oct 2008 Start date changed from September 2006 to February 2006, reported by ClinicalTrials.gov.